Showing results (91-100 of 123) with videos related to
Sort By:
Pageof 13
International Journal of Cancer|March 17, 2001
Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugateP H Houba, E Boven, I H van der Meulen-Muileman, et al.Biochemical Pharmacology|February 26, 1999
Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenograftsP H Houba, E Boven, I H van der Meulen-Muileman, et al.British Journal of Cancer|August 19, 2010
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumoursE Boven, C Massard, J P Armand, et al.Gynecologic Oncology|September 24, 2004
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancerA Clamp, M Adams, R Atkinson, et al.British Journal of Cancer|May 11, 2006
CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cellsD Fontijn, M C A Duyndam, M P A van Berkel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicinS A van Acker, E Boven, K Kuiper, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Tumour localisation with 131I-labelled human IgM monoclonal antibody 16.88 in advanced colorectal cancer patientsE Boven, H J Haisma, H Bril, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated miceM Treskes, E Boven, A A van de Loosdrecht, et al.Progress in Clinical and Biological Research|January 1, 1988
Potential advances in combination chemotherapy for advanced testicular cancerS B Kaye, G Stoter, D Sleijfer, et al.Journal of the National Cancer Institute|December 18, 1991
Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patientsH J Haisma, H M Pinedo, M A Kessel, et al.Pageof 13